Literature DB >> 8299008

Repression of cytochrome P450 by cytokines: IL-1 beta counteracts clofibric acid induction of CYP4A in cultured fetal rat hepatocytes.

J H Parmentier1, P Kremers, L Ferrari, A M Batt, J E Gielen, G Siest.   

Abstract

Interleukin-1 is known to repress a number of hepatic drug-metabolizing enzymes in rats and humans. The effect of interleukin-1 beta on lauric acid 12-hydroxylase (CYP4A family) was studied in cultured fetal rat hepatocytes after clofibric acid induction. Dexamethasone was used as an agent promoting differentiation and long-term maintenance of active hepatocytes. Dexamethasone and clofibric acid in combination allowed maximal (13.5-fold) induction of CYP4A1. Lauric acid 12-hydroxylase activity was found to increase with time in culture. Interleukin-1 beta adversely affected P4504A clofibric acid-induced activity, totally eliminating the effect of induction at doses exceeding 5 ng/ml. This repression/inhibition was dose-dependent. The mechanism by which interleukin-1 beta prevents the development of cytochrome P4504A activity is unclear.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8299008     DOI： 10.1007/BF00755608

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN： 0742-2091            Impact factor:   6.691


  18 in total

1.  Differential effects of human recombinant interleukin-1 beta on cytochrome P-450-dependent activities in cultured fetal rat hepatocytes.

Authors:  L Ferrari; P Kremers; A M Batt; J E Gielen; G Siest
Journal:  Drug Metab Dispos       Date:  1992 May-Jun       Impact factor: 3.922

Review 2.  Mechanism-based probes of the topology and function of fatty acid hydroxylases.

Authors:  P R Ortiz de Montellano; W K Chan; S F Tuck; R M Kaikaus; N M Bass; J A Peterson
Journal:  FASEB J       Date:  1992-01-06       Impact factor: 5.191

3.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators.

Authors:  I Issemann; S Green
Journal:  Nature       Date:  1990-10-18       Impact factor: 49.962

4.  Effect of interleukin 6 on phenobarbital induction of cytochrome P-450IIB in cultured rat hepatocytes.

Authors:  J F Williams; W J Bement; J F Sinclair; P R Sinclair
Journal:  Biochem Biophys Res Commun       Date:  1991-08-15       Impact factor: 3.575

5.  Induction of the hepatic mixed-function oxidase system by synthetic glucocorticoids. Transcriptional and post-transcriptional regulation.

Authors:  D L Simmons; P McQuiddy; C B Kasper
Journal:  J Biol Chem       Date:  1987-01-05       Impact factor: 5.157

6.  Induction protocols for the cytochrome P450IVA subfamily in animals and primary hepatocyte cultures.

Authors:  G G Gibson; B G Lake
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

7.  Long-term maintenance of monoxygenase activities in cultured fetal rat hepatocytes.

Authors:  A Bollinne; P Kremers; C Kolodzici; J E Gielen
Journal:  Cell Differ       Date:  1987-09

Review 8.  Interleukin 1: the first interleukin.

Authors:  F S di Giovine; G W Duff
Journal:  Immunol Today       Date:  1990-01

9.  The suppression of hepatic cytochrome P4504A mRNA mediated by the interferon inducer polyinosinic acid.polycytidylic acid.

Authors:  L C Knickle; D F Spencer; K W Renton
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

10.  Role of interleukin-1 in the depression of liver drug metabolism by endotoxin.

Authors:  P Ghezzi; B Saccardo; P Villa; V Rossi; M Bianchi; C A Dinarello
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441
View more
  4 in total

Review 1.  Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations.

Authors:  S C Piscitelli; W G Reiss; W D Figg; W P Petros
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

2.  Immunostimulating lipopeptide, LtriP (RP 56142): comparison of the effect on hepatic cytochrome P 450 modulation and radioprotection in male and female of three mouse strains.

Authors:  M Sedqi; M Delaforge; D Mansuy; B Martin; P Jollès; D Migliore-Samour
Journal:  Experientia       Date:  1995-08-16

Review 3.  Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.

Authors:  Devendra Kumar; Neerja Trivedi
Journal:  Biomed Pharmacother       Date:  2021-04-27       Impact factor: 7.419

4.  Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.

Authors:  Mahmoud A El-Ghiaty; Sherif M Shoieb; Ayman O S El-Kadi
Journal:  Med Hypotheses       Date:  2020-06-26       Impact factor: 1.538
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.